ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company focused on developing innovative drugs for patients with renal and inflammatory diseases that have high unmet medical needs. The company leverages proprietary technologies to create first-in-class therapies aimed at addressing significant medical challenges. ZyVersa does not currently sell products but is actively developing two primary drug candidates.
-
Cholesterol Efflux Mediator™ VAR 200 - An injectable drug in clinical development for treating renal diseases, with its lead indication being Focal Segmental Glomerulosclerosis (FSGS). It is designed to address multiple renal conditions, offering a "pipeline within a product" approach.
-
Inflammasome ASC Inhibitor IC 100 - A humanized monoclonal antibody targeting ASC proteins to treat multiple inflammatory diseases. Its lead indication focuses on obesity and associated metabolic complications, with potential applications in various inflammatory conditions.
You might also like
Research analysts covering ZyVersa Therapeutics.
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Numerous pharmaceutical companies, including this competitor, are engaged in the development, patenting, manufacturing, and marketing of healthcare products competitive with those that ZyVersa is developing. | |
This competitor is among the pharmaceutical companies with greater financial resources, marketing capabilities, and research and development expertise, posing significant competition to ZyVersa's product candidates. | |
Goldfinch Bio | This competitor is actively engaged in developing healthcare products that compete with ZyVersa's offerings, leveraging substantial resources and expertise. |
Boehringer Ingelheim | This competitor is part of the pharmaceutical industry landscape, offering competing products and possessing significant capabilities in manufacturing and clinical trial expertise. |
This competitor is noted for its broad range of product offerings and strong market presence, which could inhibit ZyVersa's market penetration efforts. | |
This competitor has extensive experience in obtaining patents and regulatory approvals, presenting challenges to ZyVersa's competitive positioning. | |
This competitor is highlighted as having significant intellectual property portfolios and marketing capabilities, which could impact ZyVersa's ability to compete effectively. | |
Roche | This competitor is among the companies with large direct sales forces and long-term customer relationships, posing competitive challenges to ZyVersa. |
Recent press releases and 8-K filings for ZVSA.
- Nasdaq notified ZyVersa Therapeutics that its stock closed below $1.00 for 30 consecutive business days, triggering a delisting risk.
- The company's recent reverse stock splits (1-for-35 on December 4, 2023 and 1-for-10 on April 24, 2024) rendered it ineligible for the usual cure period.
- The company intends to appeal the delisting decision by requesting a hearing, with an appeal deadline of 4:00 p.m. ET on June 3, 2025, to stay the delisting scheduled for June 5, 2025.